Liver Intra-arterial PRRT with 111In-Octreotide

The efficacy of auger and internal conversion electron emission 0f in-111 to treat neuroendocrine tumors.- Somatostatin.- Gastro-entero-pancreatic neuroendocrine tumors.- [111in-dtpa0-d-phe1] - octreotide: the ligand -the receptor-label.- Regulations and requirements of hospitals performing radio-infusions.- Intravenous radio-peptide infusion with in-octreotide.- Intra-arterial radio-peptide infusion.- Radio-peptide infusions after implementation of an intra-arterial port system.- US, CT and MRI for the evaluation of patients with neuroendocrine tumors.- Angiographic anatomy on the course of liver intra-arterial infusion.- Liver radio-infusions:  identifying anatomic variants.- Dosimetry and dose calculation: its necessity in radio-peptide therapy.- Evaluation and assessment of the radio-peptide treatment efficacy.- Intra-venous radio-peptide infusions with in-octreotide for the treatment of bronchial carcinoids.- Intra-arterial radio - peptide infusions for the treatment of colorectal carcinomas.- Intra-arterial radio-peptide infusions for the treatment of paragangliomas.- Intra-arterial radio-peptide infusions for the treatment of brain meningiomas.- Surgery in neuroendocrine tumors.- Cytoreductive surgery combined with intraperitoneal [111in-dtpa0- d-phe1]-octreotide infusions in neuroendocrine character metastases.- Patients survival followed intra-arterial versus intravenous infusions.- Complications and side effects on the course of liver-radio-infusions.- Progression free survival and response rate in neuroendocrine liver-metastasized patients, treated with in-111 octreotide.- Therapy response vs variability of tumor size, absorbed dose, and ki-67 index after in-111 octreotide intra-arterial infusions.